PureTech Health plc (PRTC)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 110.00 |
|---|---|
| 52-week range | 106.60 – 143.60 |
| Return, 1 month / 3 months | −5.2% / −10.9% |
| Return, 1 year / 3 years | −17.8% / −33.1% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 33.3% |
| Worst drawdown (1 year) | -23.3% |
| Average daily value traded | 86.17M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PureTech Health is a biotherapeutics company that invents and develops new medicines, largely by creating and growing separate companies around specific scientific ideas. Its work spans areas such as immunology, oncology and the microbiome, and it also develops digital therapeutic products. The company is based in Boston in the United States, and it advances its programmes through its own research teams and through the affiliated businesses it builds, working with partners and investors to move treatments toward patients.
PureTech Health plc trades under the code PRTC on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
PureTech Health plc (PRTC) trades on the London Exchange in UK. It last closed at GBX 110.00 on 23 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 2,209 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 17.8% and over the last three months it fell 10.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.2% | ||
| From 52-week high | -21.5% | ||
| Momentum | 26 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.9% | ||
| 6-month return | -12.6% | ||
| 12-month return, skipping the last month | -13.3% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.3% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 86.17M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −4.0% |
|---|---|
| 1 month | −5.2% |
| 3 months | −10.9% |
| 6 months | −12.6% |
| 1 year | −17.8% |
| 3 years | −33.1% |
| 5 years | −68.3% |
Signals
| 50-day / 200-day average | 116.78 / 123.92 |
|---|---|
| Golden / death cross (60 days) | Death, 57 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.42 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.